NICE is recommending Janssen’s hepatitis C pill Incivo for funding on the NHS in England. The drug has bypassed the …

I read recently that less than 2% of NHS Trust board meeting agenda items require decisions. What happens during the …

GlaxoSmithKline has shed more of its non-core consumer health OTC products in a £391 million sale, including a German manufacturing …

NICE has changed its mind on Novartis’ multiple sclerosis pill Gilenya, and is now recommending the drug in a subgroup …
An updated set of mandatory requirements for Marketing Authorisation Holders (MAH) to comply with Article 57(2) of the forthcoming new …
PAN Advertising has made four new appointments since Jon Linscott took over as managing director in February, with two new …
GlaxoSmithKline has hired two technology companies to help it optimise digital communications in consumer healthcare and pharmaceuticals.The firm will work …
A new photodynamic therapy treatment for human papilloma virus (HPV) associated diseases of the cervix has shown potential in a …

NICE has given a limited recommendation to Boehringer Ingelheim’s blood thinner Pradaxa. The watchdog said in final guidance that Pradaxa …
Sanofi has decided to close down a manufacturing facility in the North East of the UK with the loss of …
The regulatory environments within the industry continue to change and vary internationally. Cmed’s regulatory and medical professionals keep track of …
Pharmaceutical markets across Europe have been badly hit by the economic crisis, with revenues in some countries being decimated by …
The European Medicines Agency has launched a pilot scheme that allows pharma firms to submit new drug applications electronically. The …
Last month the Department of Health released ideas for new apps aimed at patients and doctors. Below are some video …

Scotland’s medicines regulator has turned down Janssen’s prostate cancer pill Zytiga, leading to a backlash from charities. The Scottish Medicines …

Roche’s Zelboraf has been launched in the UK to treat the deadliest form of skin cancer. Zelboraf (vemurafenib) is the …

AstraZeneca has said it filed a lawsuit against the US FDA in a bid to block approval of generic versions …

Pfizer has walked away from a research deal with India’s biggest biotech firm Biocon. Both companies were working on a …
Manufacturing Chemist, an established publication in the biopharmaceutical industry, recently approached SHL to share with their readers the company’s knowledge …

Merck has been warned by the FDA that it must carry out a post-marketing safety study on diabetes treatments Januvia …